• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Ajay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy Officer

    6/23/25 8:00:00 AM ET
    $LAZ
    $SNN
    Investment Managers
    Finance
    Industrial Specialties
    Health Care
    Get the next $LAZ alert in real time by email

    Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will report to Chief Executive Officer Deepak Nath and join the Smith+Nephew Executive Committee. 



    As both a senior management consultant and investment banker, Ajay has advised CEOs and Boards at some of the world's leading healthcare companies, helping deliver substantial shareholder value. 

    Ajay's experience includes 25 years with McKinsey & Company where he was a Senior Partner and held multiple leadership roles including Global Head of Strategy across all industries, Global Head of Strategy and M&A for Life Sciences and Global Head of Life Sciences R&D. 

    Following that, Ajay served as a Managing Director in the Financial Advisory Healthcare Group of Lazard Ltd (NYSE:LAZ) where he was the Global Head of Medical Technology, Diagnostics and Tools. More recently, Ajay founded and led Bluish Capital, a strategy and financial advisory firm focused on deploying growth capital to support high quality, recently FDA approved assets.

    Ajay has bachelor's degrees in Physics and Computer Science from Angelo State University, and both a master's degree and a doctorate in Molecular Biophysics and Biochemistry from Yale University. 

    Deepak Nath, Chief Executive Officer, commented: "Ajay's unique blend of scientific rigor, strategic insight, business development, integrations, and operational excellence, combined with his entrepreneurial leadership style, makes him exceptionally well-suited to help shape our future. We are pleased to have him join our leadership team at this exciting time for the company."

    - ends –



    Enquiries



    Investors
     
    Andrew Swift+44 (0) 1923 477433
    Smith+Nephew 
      
    Media 
    Charles Reynolds +44 (0) 1923 477314
    Smith+Nephew 
      
    Susan Gilchrist / Ayesha Bharmal+44 (0) 20 7404 5959
    Brunswick 

     

    About Smith+Nephew

    Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited'. Our 17,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

    Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 ((LSE:SN, NYSE:SNN). The terms ‘Group' and ‘Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

    For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

      

    Forward-looking Statements

    This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.



    ◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.



    Primary Logo

    Get the next $LAZ alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LAZ
    $SNN

    CompanyDatePrice TargetRatingAnalyst
    Smith & Nephew SNATS Inc.
    $SNN
    4/25/2025Buy → Hold
    HSBC Securities
    Lazard Inc.
    $LAZ
    4/7/2025$56.00 → $33.00Equal-Weight → Underweight
    Morgan Stanley
    Smith & Nephew SNATS Inc.
    $SNN
    3/12/2025Buy → Neutral
    UBS
    Lazard Inc.
    $LAZ
    1/3/2025Outperform → Peer Perform
    Wolfe Research
    Lazard Inc.
    $LAZ
    12/20/2024$65.00 → $57.00Outperform → Mkt Perform
    Keefe Bruyette
    Lazard Inc.
    $LAZ
    12/9/2024$60.00 → $63.00Overweight → Equal-Weight
    Morgan Stanley
    Smith & Nephew SNATS Inc.
    $SNN
    11/6/2024Buy → Hold
    Berenberg
    Smith & Nephew SNATS Inc.
    $SNN
    11/1/2024Buy → Hold
    Deutsche Bank
    More analyst ratings

    $LAZ
    $SNN
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Lazard Inc.

      SCHEDULE 13G/A - Lazard, Inc. (0001311370) (Subject)

      7/17/25 7:54:40 PM ET
      $LAZ
      Investment Managers
      Finance
    • SEC Form 6-K filed by Smith & Nephew SNATS Inc.

      6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

      7/11/25 6:59:11 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by Smith & Nephew SNATS Inc.

      6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

      7/1/25 11:55:37 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $LAZ
    $SNN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lazard Reports June 2025 Assets Under Management

      Lazard, Inc. (NYSE:LAZ) reported today that its preliminary assets under management ("AUM") as of June 30, 2025 totaled approximately $248.4 billion. The month's AUM included market appreciation of $5.4 billion, net inflows of $4.6 billion, and FX appreciation of $3.1 billion. Preliminary average AUM for the quarter ended June 30, 2025 was $238.6 billion.   LAZARD, INC. ASSETS UNDER MANAGEMENT ("AUM") (unaudited) ($ in millions)         As of:       June 30,   May 31,       20251   2025     Equity   $ 192,250   $ 180,510     Fixed Income     47,057

      7/11/25 6:45:00 AM ET
      $LAZ
      Investment Managers
      Finance
    • Lazard to Announce Second Quarter and First Half 2025 Financial Results

      Lazard, Inc. (NYSE:LAZ) will announce its second quarter and first half 2025 financial results in a press release to be issued Thursday morning, July 24, 2025. The press release will be available in the News & Announcements section of Lazard's website at www.lazard.com. Lazard will host a conference call at 8:00 a.m. ET on July 24, 2025, to discuss the company's financial results. The conference call can be accessed via a live audio webcast available through the Investor Relations section of Lazard's website at www.lazard.com, or by dialing 1 800-445-7795 (toll-free within the U.S. and Canada) or +1 785-424-1699 (outside of the U.S. and Canada) 15 minutes prior to the start of the call an

      7/9/25 8:00:00 AM ET
      $LAZ
      Investment Managers
      Finance
    • Smith+Nephew expands market-leading fixation strength of Q-FIX™ All-Suture Anchor portfolio with new knotless option

      Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the release of its Q-FIX KNOTLESS All-Suture Anchor for soft tissue-to-bone fixation indications across multiple joint spaces including Shoulder, Hip, and Foot & Ankle.  Building on the long-standing success and performance of the best-in-class anchor fixation strength of the Q-FIX Family versus competitive devices*, the new Q-FIX KNOTLESS All-Suture Anchor raises the bar for all-suture anchor technology. With proprietary features and capabilities, the Q-FIX KNOTLESS All-Suture Anchor aims to set a new benchmark for fixation strength and offer surgeons a reason to reassess their joint repair approach, inclu

      7/7/25 10:00:00 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $LAZ
    $SNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Lazard Inc.

      SC 13G - Lazard, Inc. (0001311370) (Subject)

      11/8/24 2:17:07 PM ET
      $LAZ
      Investment Managers
      Finance
    • SEC Form SC 13D filed by Smith & Nephew SNATS Inc.

      SC 13D - SMITH & NEPHEW PLC (0000845982) (Subject)

      7/9/24 12:00:10 PM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Lazard LTD. Lazard LTD. (Amendment)

      SC 13G/A - Lazard, Inc. (0001311370) (Subject)

      2/14/24 9:41:26 AM ET
      $LAZ
      Investment Managers
      Finance

    $LAZ
    $SNN
    Financials

    Live finance-specific insights

    See more
    • Lazard to Announce Second Quarter and First Half 2025 Financial Results

      Lazard, Inc. (NYSE:LAZ) will announce its second quarter and first half 2025 financial results in a press release to be issued Thursday morning, July 24, 2025. The press release will be available in the News & Announcements section of Lazard's website at www.lazard.com. Lazard will host a conference call at 8:00 a.m. ET on July 24, 2025, to discuss the company's financial results. The conference call can be accessed via a live audio webcast available through the Investor Relations section of Lazard's website at www.lazard.com, or by dialing 1 800-445-7795 (toll-free within the U.S. and Canada) or +1 785-424-1699 (outside of the U.S. and Canada) 15 minutes prior to the start of the call an

      7/9/25 8:00:00 AM ET
      $LAZ
      Investment Managers
      Finance
    • Lazard Global Total Return and Income Fund Declares Monthly Distribution and Issues Estimated Sources of the Distribution Announced in May

      Lazard Global Total Return and Income Fund, Inc. (the "Fund") (NYSE:LGI) is confirming today, pursuant to its Managed Distribution Policy, as previously authorized by its Board of Directors, a monthly distribution of $0.14646 per share on the Fund's outstanding common stock. The distribution is payable on July 22, 2025 to shareholders of record on July 10, 2025. The ex-dividend date is July 10, 2025. The Fund will pay a previously declared distribution today, June 24, 2025. The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid, including today's distribution, from the following sources: net investment income, net realized ca

      6/24/25 5:12:00 PM ET
      $LAZ
      $LGI
      Investment Managers
      Finance
    • Lazard Global Total Return and Income Fund Declares Monthly Distribution and Issues Estimated Sources of the Distribution Announced in April

      Lazard Global Total Return and Income Fund, Inc. (the "Fund") (NYSE:LGI) is confirming today, pursuant to its Managed Distribution Policy, as previously authorized by its Board of Directors, a monthly distribution of $0.14646 per share on the Fund's outstanding common stock. The distribution is payable on June 24, 2025 to shareholders of record on June 10, 2025. The ex-dividend date is June 10, 2025. The Fund will pay a previously declared distribution today, May 22, 2025. The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid, including today's distribution, from the following sources: net investment income, net realized capi

      5/22/25 4:15:00 PM ET
      $LAZ
      $LGI
      Investment Managers
      Finance

    $LAZ
    $SNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Soto Alexandra sold $3,763,016 worth of shares (85,894 units at $43.81), decreasing direct ownership by 43% to 113,872 units (SEC Form 4)

      4 - Lazard, Inc. (0001311370) (Issuer)

      6/13/25 5:47:32 PM ET
      $LAZ
      Investment Managers
      Finance
    • SEC Form 4 filed by Director Achleitner Ann-Kristin

      4 - Lazard, Inc. (0001311370) (Issuer)

      6/4/25 5:50:58 PM ET
      $LAZ
      Investment Managers
      Finance
    • SEC Form 4 filed by Director Harrison Peter

      4 - Lazard, Inc. (0001311370) (Issuer)

      6/4/25 5:50:47 PM ET
      $LAZ
      Investment Managers
      Finance

    $LAZ
    $SNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Smith & Nephew downgraded by HSBC Securities

      HSBC Securities downgraded Smith & Nephew from Buy to Hold

      4/25/25 8:30:48 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Lazard downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Lazard from Equal-Weight to Underweight and set a new price target of $33.00 from $56.00 previously

      4/7/25 7:56:16 AM ET
      $LAZ
      Investment Managers
      Finance
    • Smith & Nephew downgraded by UBS

      UBS downgraded Smith & Nephew from Buy to Neutral

      3/12/25 7:34:02 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $LAZ
    $SNN
    Leadership Updates

    Live Leadership Updates

    See more
    • Lazard Welcomes Klaus H. Hessberger as Managing Director and Global Co-Head of Financial Sponsors Group

      Lazard, Inc. (NYSE:LAZ) today announced that Klaus H. Hessberger has been appointed to the firm as Managing Director, Global Co-Head, and Head of Europe for Lazard's Financial Sponsors Group, based in London. Adam Cady, previously Lazard's Head of Large-Cap Financial Sponsor Coverage North America in New York, has also been named Global Co-Head of the Global Financial Sponsors Group, running the team together with Klaus. These appointments reflect Lazard's expanding connectivity and partnership with alternative asset managers, which continues to be a principal area of focus and a major source of future growth for the firm globally. Lazard's recruiting efforts are also a key contributor

      7/1/25 1:50:00 AM ET
      $LAZ
      Investment Managers
      Finance
    • Ajay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy Officer

      Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will report to Chief Executive Officer Deepak Nath and join the Smith+Nephew Executive Committee.  As both a senior management consultant and investment banker, Ajay has advised CEOs and Boards at some of the world's leading healthcare companies, helping deliver substantial shareholder value.  Ajay's experience includes 25 years with McKinsey & Company where he was a Senior Partner and held multiple leadership roles including Global Head of Strategy across all industries, Global Head of Strategy

      6/23/25 8:00:00 AM ET
      $LAZ
      $SNN
      Investment Managers
      Finance
      Industrial Specialties
      Health Care
    • Lazard Asset Management Appoints Eric Van Nostrand Global Head of Markets and Chief Economist

      Lazard Asset Management (LAM) today announced that Eric Van Nostrand has joined the firm as Global Head of Markets and Chief Economist. In this newly created role reporting to LAM CEO Evan Russo, Mr. Van Nostrand will work across the firm's investment and research teams, bringing additional macro insights and market perspectives to our investment decisions. As a member of the executive leadership team for Lazard's Asset Management business, he will lead economic and market analysis for the firm and its clients, including oversight and development of investment content. "Financial markets around the world are becoming increasingly complex, with global economic volatility and policy decis

      6/2/25 9:30:00 AM ET
      $LAZ
      Investment Managers
      Finance